A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma

被引：1
|
作者：
Luscan, Gerald [1 ]
Paccagnella, Luisa [2 ]
Patel, Krish [3 ]
机构：
[1] Pfizer Int Org, Global Prod Dev, Paris, France
[2] Pfizer Inc, Groton, CT 06340 USA
[3] Swedish Canc Inst, Seattle, WA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182275
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial
    Lin, Ningjing
    Sun, Xiuhua
    Zhou, Hui
    Zou, Liqun
    Zhou, Keshu
    Liu, Lihong
    Yang, Haiyan
    Hu, Kai
    Cai, Qingqing
    Liu, Yao
    Jin, Jie
    Zhang, Liling
    Li, Wenyu
    Guo, Ye
    Yang, Wei
    Luo, Feng
    Wang, Zhenguang
    Zhu, Rong
    Yang, Lei
    Song, Dan
    Song, Yuqin
    Zhu, Jun
    HAEMATOLOGICA, 2025, 110 (03) : 683 - 692
  • [22] An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma
    Younes, Anas
    Salles, Gilles
    Bociek, R. Gregory
    Martinelli, Giovanni
    Caballero, Dolores
    Gonzalez Barca, Eva
    Mukherjee, Nabanita
    Williams, Lisa
    Herbst, Fabian
    Tavorath, Ranjana
    Kim, Won Seog
    BLOOD, 2014, 124 (21)
  • [23] GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Phillips, Tycel
    Matasar, Matthew
    Eyre, Toby A.
    Gine, Eva
    de L'Etang, Audrey Filezac
    Byrne, Ben
    Lundberg, Linda
    Padovani, Alejandra
    Boetsch, Christophe
    Bottos, Alessia
    Qayum, Naseer
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S515 - S515
  • [24] Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
    Cartron, Guillaume
    Houot, Roch
    Al Tabaa, Yassine
    Le Bras, Fabien
    Ysebaert, Loic
    Choquet, Sylvain
    Jardin, Fabrice
    Bay, Jacques-Olivier
    Gros, Francois-Xavier
    Morschhauser, Franck
    Casasnovas, Olivier
    Gastinne, Thomas
    Thieblemont, Catherine
    Joris, Magalie
    Ricard, Laure
    Regny, Caroline
    La Rochelle, Laurianne Drieu
    Feugier, Pierre
    Marcais, Ambroise
    Griolet, Samuel
    Tarte, Karin
    Laurent, Camille
    Sesques, Pierre
    NATURE CANCER, 2025,
  • [25] Glofitamab in relapsed and/or refractory diffuse large B cell lymphoma after at least two lines of treatment
    Daguerre, Valentin
    Croizier, Carolyne
    BULLETIN DU CANCER, 2024, 111 (09) : 794 - 796
  • [26] Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
    Daver, Naval G.
    Dail, Monique
    Garcia, Jacqueline S.
    Jonas, Brian A.
    Yee, Karen W. L.
    Kelly, Kevin R.
    Vey, Norbert
    Assouline, Sarit
    Roboz, Gail J.
    Paolini, Stefania
    Pollyea, Daniel A.
    Tafuri, Agostino
    Brandwein, Joseph M.
    Pigneux, Arnaud
    Powell, Bayard L.
    Fenaux, Pierre
    Olin, Rebecca L.
    Visani, Giuseppe
    Martinelli, Giovanni
    Onishi, Maika
    Wang, Jue
    Huang, Weize
    Green, Cherie
    Ott, Marion G.
    Hong, Wan-Jen
    Konopleva, Marina Y.
    Andreeff, Michael
    BLOOD, 2023, 141 (11) : 1265 - 1276
  • [27] A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Zhu, Jun
    Song, Yuqin
    Guo, Ye
    Zhou, Keshu
    Li, Wenyu
    Yang, Yu
    Cai, Qingqing
    Wang, Zhao
    Yang, Haiyan
    BLOOD, 2023, 142
  • [28] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group
    Martin, Alejandro
    Redondo, Alba M.
    Dlouhy, Ivan
    Salar, Antonio
    Gonzalez-Barca, Eva
    Canales, Miguel
    Montes-Moreno, Santiago
    Ocio, Enrique M.
    Lopez-Guillermo, Armando
    Caballero, Dolores
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 245 - 252
  • [29] Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma
    Lust, John A.
    Barranco, Charles
    Usmani, Saad Z.
    van Rhee, Frits
    Hamadani, Mehdi
    Thompson, John
    Taylor, Catherine A.
    Dondero, Richard
    Browne, Leslie J.
    Siegel, David
    Bensinger, William I.
    BLOOD, 2013, 122 (21)
  • [30] Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data
    Atesoglu, Elif Birtas
    Gulbas, Zafer
    Uzay, Ant
    Ozcan, Muhit
    Ozkalemkas, Fahir
    Dal, Mehmet Sinan
    Kalyon, Hakan
    Akay, Olga Meltem
    Deveci, Burak
    Bekoz, Huseyin
    Sevindik, Omur Gokmen
    Toptas, Tayfur
    Yilmaz, Fergun
    Koyun, Derya
    Alkis, Nihan
    Alacacioglu, Inci
    Sonmez, Mehmet
    Yavasoglu, Irfan
    Tombak, Anil
    Mehtap, Ozgur
    Kurnaz, Fatih
    Yuce, Orhan Kemal
    Karakus, Volkan
    Turgut, Mehmet
    Kurekci, Derya Deniz
    Ayer, Mesut
    Keklik, Muzaffer
    Buyuktas, Deram
    Ozbalak, Murat
    Ferhanoglu, Burhan
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 663 - 673
12345